Bharat Parenterals Ltd — Updates, 03-05-2025: Company Update

Bharat Parenterals’ subsidiary, Innoxel Lifesciences, has successfully completed the U.S. FDA inspection at its Vadodara manufacturing facility, receiving only one minor procedural observation. This positive outcome underscores Innoxel's strong quality and compliance standards, reinforcing its position in regulated markets and readiness to supply high-quality sterile injectable and complex dosage pharmaceutical products globally. The successful inspection supports the company’s growth strategy in regulated international markets and benefits stakeholders by enhancing operational credibility.